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The tumor suppressor adenomatous polyposis coli (APC) is implicated in regulating multiple stages of the cell cycle. APC
participation in G1/S is attributed to its recognized role in Wnt signaling. APC function in the G2/M transition is less well
established. To identify novel protein partners of APC that regulate the G2/M transition, APC was immunoprecipitated
from colon cell lysates and associated proteins were analyzed by matrix-assisted laser desorption ionization/time of flight
(MALDI-TOF). Topoisomerase II (topo II) was identified as a potential binding partner of APC. Topo II is a critical
regulator of G2/M transition. Evidence supporting an interaction between endogenous APC and topo II was obtained by
coimmunoprecipitation, colocalization, and Förster resonance energy transfer (FRET). The 15-amino acid repeat region of
APC (M2-APC) interacted with topo II when expressed as a green fluorescent protein (GFP)-fusion protein in vivo.
Although lacking defined nuclear localization signals (NLS) M2-APC predominantly localized to the nucleus. Further-
more, cells expressing M2-APC displayed condensed or fragmented nuclei, and they were arrested in the G2 phase of the
cell cycle. Although M2-APC contains a -catenin binding domain, biochemical studies failed to implicate -catenin in
the observed phenotype. Finally, purified recombinant M2-APC enhanced topo II activity in vitro. Together, these data
support a novel role for APC in the G2/M transition, potentially through association with topo II.
INTRODUCTION
The tumor suppressor protein adenomatous polyposis coli
(APC) is inactivated in 80% of all colorectal cancers (Kin-
zler and Vogelstein, 1996). The detection of mutant APC in
the earliest stages of polyp development supports the idea
that mutation of APC is an initiating event in colon carcino-
genesis. The most common form of APC mutation results in
elimination of the carboxy-terminal half of the APC protein.
Because APC is a large, multidomain protein, APC trunca-
tion is predicted to impact several cellular mechanisms, the
extent of which we are only beginning to understand.
There is accumulating evidence supporting a role for APC
in the regulation of cell cycle. Overexpression of APC in
NIH3T3 fibroblasts and colon cancer cell lines leads to G1
cell cycle arrest (Ishidate et al., 2000; Heinen et al., 2002),
presumably by repressing transcription of Wnt targets such
as cyclin D1. APC may also participate directly in mitosis
because it is transiently hyperphosphorylated in the M
phase of the cell cycle (Bhattacharjee et al., 1996), accumu-
lates at the microtubule-organizing center (Olmeda et al.,
2003), and associates with the kinetochore in dividing cells
(Fodde et al., 2001; Kaplan et al., 2001). A role for APC in
mitosis might be critical for regulation of genomic stability
and proper chromosome segregation. APC stabilized by zinc
treatment induces G2/M cell cycle arrest in colon cancer
cells (Jaiswal and Narayan, 2004). However, to date, little is
known about the underlying mechanism by which APC
participates in the G2/M cell cycle transition.
Here, we report identification of topoisomerase II (topo
II) as a potential APC-binding protein. Topo II enzyme
catalyzes DNA topology changes by introducing double-
strand DNA breaks that facilitate DNA strand passage and
subsequent DNA religation (Wang, 1996; Champoux, 2001;
Fortune and Osheroff, 2001; McClendon and Osheroff, 2007).
Topo II has been implicated in several cellular functions
such as DNA replication and chromosome condensation
(Wang, 1996; Nitiss, 1998; Fortune and Osheroff, 2000;
Champoux, 2001; Wang, 2002; McClendon and Osheroff,
2007), and it seems to be essential in the control of the G2/M
decatenation checkpoint during cell division (Downes et al.,
1994). Topo II was also found to be deregulated in colon
cancers, with its expression limited to the proliferative zone
in the normal colon, but up-regulated and widespread in
colon cancer tissue (Murphy et al., 2001). At primary loca-
tions of recurrent malignant colon tumors after chemother-
apy, the number of topo II-positive cells is greatly in-
creased compared with primary sites with no recurrence
(Lazaris et al., 2002), suggesting that changes in topo II
expression occur subsequent to APC mutation. Together,
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these observations make topo II an attractive candidate for
mediating the G2/M cell cycle transition.
Overexpression of an APC fragment that interacts with
topo II in various colon cancer cells lines led to abnormal
nuclear morphology and cell cycle inhibition in G2. Our data
suggest a novel role for nuclear APC in the regulation of cell
cycle progression, potentially through an interaction with
topo II.
MATERIALS AND METHODS
Cell Culture and DNA Constructs
HCT116w cells (a generous gift from Dr. Bert Vogelstein) were grown in
McCoy’s 5A medium (Invitrogen) supplemented with 10% fetal bovine serum
(FBS) (HyClone Laboratories, Logan, UT). Expression constructs for APC
fragments fused to green fluorescent protein (GFP) were kindly provided by
Dr. Kozo Kaibuchi and have been described previously (Watanabe et al.,
2004).
Antibodies and Immunofluorescence Microscopy
Immunostaining was performed as described previously (Neufeld and White,
1997) and the following antibodies were used: anti-APC (ab-7, 1:50; Calbio-
chem, San Diego, CA), anti-APC (ab-4, 1:2000; Calbiochem), anti-APC (ab-1,
1:100; Calbiochem), anti-topo II (1:100; Research Diagnostics, Flanders, NJ),
anti-phospho-histone H3 (1:500; Millipore, Billerica, MA), anti--catenin (1:
200; BD Biosciences Transduction Laboratories, Lexington, KY), and anti-
proliferating cell nuclear antigen (PCNA, 1:1000; BD Biosciences Transduction
Laboratories); goat anti-mouse immunoglobulin G (IgG) Alexa 488 (1:1000;
Invitrogen, Carlsbad, CA), goat anti-rabbit IgG Alexa 568 (1:1000; Invitrogen),
and goat anti-mouse IgG Alexa 610-R-phycoerythrin (1:500; Invitrogen). DNA
was labeled with Topro-3 (1:500; Invitrogen), or 4,6-diamidino-2-phenylin-
dole (DAPI) (1:5000; Invitrogen). Two-dimensional (2-D) and three-dimen-
sional (3-D) distributions of immunofluorescent signals were examined using
a Yokugawa-type spinning disk confocal microscope equipped with an Olym-
pus 150 objective with a numerical aperture of 1.45 and 1KX1K EMCCD
(Olympus and Intelligent Imaging Innovations, Denver, Co.). From 200 cells
that were viewed, 50 cells were randomly chosen to be imaged. At least 24
image frames were collected at z-intervals of 100 nm for image sets where 3-D
colocalization was examined. No deconvolution was performed. All raw
confocal image series were analyzed by ImageJ program (National Institutes
of Health, Bethesda, MD) and the JACoP plugin without further processing.
Mitotic indices were determined by counting DAPI-stained mitotic cells in a
field of 100 cells for each repetition.
Protein Colocalization Analysis
Colocalization coefficients were calculated using ImageJ and the JACoP plu-
gin (Bolte and Cordelieres, 2006). Using Costes’ method of automatic thresh-
olding, a Pearson’s coefficient was calculated for pixels within all of the
calculated regions of interest in an image where Alexa 488 and Alexa 568
fluorescence were each detected at levels significantly above background.
Mander’s coefficients were also calculated to determine the degree of overlap
between the corresponding regions of detected signals.
Förster Resonance Energy Transfer (FRET) Analysis
Evidence of FRET between secondary fluorophores was detected using a
Zeiss 510 Meta spectral imaging upright laser scanning confocal microscope
(Carl Zeiss, Thornwood, NY). Donor fluorescence, alternatively from Alexa
488 or Alexa 610-R-phycoerythrin was photobleached by passing the beam of
the 543-nm laser (at 100% output) over defined regions of interest for 75
iterations or by using 200 passes of the 633-nm laser (also 100% output).
Proximity of the two proteins was determined by calculating the mean FRET
efficiency between donor and acceptor according to the method of Kenworthy
and Edidin (1998), where E  100(Alexa 488post  Alexa 488pre)/Alexa 488post
or E  100(Alexa 610-R-PEpost  Alexa 610-R-PEpre)/Alexa 610-R-PEpost. All
pixels within the photobleached regions were used for these calculations.
Error bars indicate the SEM. Three-dimensional reconstructions and projec-
tions were also performed with ImageJ.
Immunoprecipitation and Western Immunoblots
Immunoprecipitation (IP) and Western immunoblots (IB) were performed
using modified standard protocols. Cells at 90% confluence were lysed in lysis
buffer (50 mM Tris, pH 7.5, 0.1% NP-40, 100 mM NaCl, 1 mM MgCl2, 5 mM
EDTA, protease inhibitor cocktail [Sigma-Aldrich, St. Louis, MO], and Halt
phosphatase inhibitor cocktail [Pierce Chemical, Rockford, IL]) on ice for 30
min. Cell lysates were sonicated for 10 pulses, level 1 with 10% output, three
times. Specific antibodies were preincubated with protein A Dynabeads (In-
vitrogen) for 2 h at room temperature. Dynabeads saturated with antibodies
were added to 1 mg of soluble lysate and incubated overnight at 4°C. IP
pellets were subject to two washes of 15 min by using lysis buffer and one
wash using phosphate-buffered saline (PBS)/Tween 20 at 4°C. The following
antibodies were used for IP: anti-topo II sera (a generous gift from Dr. Joe
Holden), affinity-purified anti-APC-M2 rabbit polyclonal antibody made
against amino acids 1000–1326, and polyclonal anti-GFP (Invitrogen). Immu-
noblots were probed with the following antibodies: anti-APC (ab-1, 1:100;
Calbiochem), anti-APC-M2 polyclonal (1:4000), anti--catenin (1:2000; Sigma-
Aldrich), anti-topo II (1:1000; Research Diagnostics), anti-topo II (1:1000;
Santa Cruz Biotechnology, Santa Cruz, CA), and anti--tubulin (1:2000; Cal-
biochem).
Transfection and Reporter Gene Assay
HCT116w, SW480, and HCA7 cells were transfected using Lipofectamine
2000 reagent according to the manufacturer’s protocol (Invitrogen). For lucif-
erase assays, HCT116w cells grown in 24-well plates were cotransfected
with 2 g of the GFP-M2-APC or GFP expression construct, 100 ng of the
TCF-reporter construct SuperTOP-flash or FOPflash (Millipore), and 50 ng of
the pRL-TK Renilla luciferase construct (Promega, Madison, WI) as a control
to normalize the transfection efficiency. After 24 h, cells were harvested and
luciferase activities were determined using Dual-Luciferase assay system
(Promega) and a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA).
SuperTOP-flash and FOPflash luciferase activities were first normalized by
pRL-TK Renilla luciferase, and then the normalized SuperTOP-flash luciferase
activity was divided by normalized FOPflash luciferase activity to calculate
relative -catenin activity.
Fluorescence Activated Cell Sorting (FACS) Analysis
Propidium iodide staining of GFP-expressing cells in suspension was per-
formed using a standard protocol as described previously (Lamm et al., 1997).
HCT116w cells at 35% confluence were transfected using Lipofectamine
2000 (Invitrogen). Thirty hours after transfection, cells were fixed with 2%
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) on ice for 1 h,
followed by overnight permeabilization by using 70% ethanol in PBS. Rehy-
drated cells were then stained with 40 g/ml propidium iodide (Sigma-
Aldrich) in PBS for 30 min at 37°C. FACS analysis was performed using an
FACScan (BD Biosciences, San Jose, CA).
Topo II Assays and Recombinant Proteins
To generate recombinant S tag fused M2-APC, the corresponding cDNA for
APC (amino acids 1000–1326) was subcloned into a pET-30a() vector. Both
tags (S and His) were fused to the amino terminus of the protein. The
expression and purification of S-M2-APC fusion protein was performed as
described previously (Azuma et al., 2003). Recombinant human topo II was
made as described previously (Worland and Wang, 1989; Kingma et al., 1997).
In vitro topo II relaxation and decatenation assays were performed as
described previously (Fortune and Osheroff, 2001).
RESULTS
Endogenous Full-Length APC Associates with Topo II
To identify novel APC-binding proteins that could potentially
function to regulate cell cycle progression, we immunoprecipi-
tated APC from HCT116 cell lysates, resolved precipitated
proteins by SDS-polyacrylamide gel electrophoresis, and visu-
alized these proteins using Coomassie Blue stain. One protein
in a 170-kDa band unique to the APC precipitation was iden-
tified by MALDI-TOF analysis as topo II (Neufeld and White,
unpublished data).
We verified the APC–topo II interaction in both HCT116
cells and cells derived from this cell line. Although HCT116
cells were initially cultured from human colon cancer tissue,
they express full-length APC and maintain a stable karyo-
type. The original HCT116 cell line possesses one wild-type
and one mutant -catenin allele. The mutant allele encodes
a stabilized version of -catenin, which is not down-regu-
lated by APC. The HCT116w line we use for most experi-
ments was engineered to eliminate the mutant -catenin
allele; thus, it expresses only wild-type -catenin protein
(Chan et al., 2002). Full-length endogenous APC coimmuno-
precipitated with topo II in HCT116 cell lysates (Figure
1A). No full-length APC was precipitated with control rabbit
IgG. In reciprocal experiments, topo II coprecipitated with
full-length APC by using an affinity-purified APC antibody,
but not with preimmune sera (Figure 1B, left). We consis-
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tently detected nearly 2% of the total topo II coprecipitated
with APC (Figure 1B, right). In contrast, although topoisom-
erase II is 75% identical to topo II, topo II did not
coprecipitate with APC (Figure 1B, left). This apparent bind-
ing preference for topo II over topo II increases the like-
lihood that the APC-topo II interaction is specific.
The subcellular distribution of endogenous APC and topo
II further implicated topo II as a binding partner of APC.
Endogenous APC was found to colocalize with topo II
within single confocal slices taken through the nucleus
where both occur as overlapping puncta (Figure 1Ca). When
the entire cell thickness was visualized by a series of confo-
cal images captured in the z-plane, areas of overlap were
apparent throughout the nuclei (Figure 1Cb). To show the
areas of overlap from an entire cell thickness as a single
image, overlapping signals in the 3-D data sets were pro-
jected onto a 2-D surface and are displayed in yellow (Figure
1Cc). The degree of overlap between the corresponding
regions was calculated for each 2-D confocal section and is
displayed as the average for the entire imaged volume. On
average, 1.9% of the topo II signal coincided with APC, and
10% of the APC signal coincided with topo II (Figure 1Cd).
To further examine the association between APC and topo
II, we analyzed FRET between the two immunolabeled pro-
teins in fixed, permeabilized HCT116w cells (Figure 1D).
Given the nature of FRET, it is estimated that energy transfer
would be detected only if two antibody-labeled proteins are
30 nm apart. Detection of an average energy transfer effi-
ciency (E) of 20.8% between immunolabeled Alexa 488-APC
and Alexa 568-topo II within photobleached regions of inter-
est indicates that endogenous APC and topo II are in prox-
imity and is consistent with a direct interaction in colon epi-
thelial cells. This value is significantly more positive than
measurements performed on cells in which photobleaching
was omitted (E  0.9%). Likewise, cells transiently express-
ing GFP showed no energy transfer between endogenous topo
II and exogenous GFP (E  6.6%), even though GFP was
abundant in the nucleus (see, e.g., Figure 5A).
The 15-Amino Acid Repeat Region of APC Colocalizes
with Topo II, Alters Nuclear Morphology, and Causes
Cell Cycle Arrest in G2
APC is a 310-kDa protein with several distinct protein bind-
ing domains (Figure 2A). To identify potential topo II
Figure 1. Endogenous topo II associates with
endogenous full-length APC. (A) Endogenous
full-length APC coimmunoprecipitated with
topo II by using anti-topo II rabbit sera, but
not using rabbit IgG. P, precipitated proteins; S,
nonprecipitated supernatant proteins. Repre-
sentative blot from eight independent experi-
ments. (B) Full-length APC immunoprecipi-
tated with affinity-purified polyclonal anti-APC
sera (left and middle). Endogenous topo II
(top) coimmunoprecipitated with the endoge-
nous full-length APC, whereas topo II did not
(bottom). Quantification of the band intensity
from three independent experiments revealed
1.8% of the total topo II coprecipitated with
full-length APC (right). Representative blots
from seven independent experiments. (C) Colo-
calization of endogenous APC and topo II in
HCT 116w cells by using APC antibody (ab-7),
polyclonal topo II antibody, and confocal mi-
croscopy. (a) Confocal image shows APC
(green) and topo II (red) colocalized in the
nucleus (yellow in merge). Bar, 5 m. (b) Con-
focal images through the entire cell thickness
were collected for APC (green) and topo II
(red) and are shown as a projection of the 3-D
Z-series images. (c) Overlapping pixels for the
Z-series images in b are projected and shown in
yellow. (d) Graph shows the average number of
overlapping pixels calculated from six individ-
ual Z-series images; 1.9% of the topo II pixels
overlap with APC, whereas 10% of the APC
pixels overlap with topo II. (D) Measurements
of FRET between APC-Alexa 488 and topo II-
Alexa 568 were performed using the method of
donor fluorescence sensitization after acceptor
photobleaching in fixed samples of immun-
ofluorescently labeled HCT116w cells. Endog-
enous APC was labeled using either anti-APC
ab-1 or anti-APC ab-7 followed by goat anti-
mouse Alexa 488 secondary antibody. Endoge-
nous topo II was labeled using anti-topo II
antibody followed by goat anti-rabbit Alexa 568
secondary antibody. Energy transfer efficiencies (E) between immunolabeled Alexa 488-APC and Alexa 568-topo II were 20.8% (gray bar,
left, n  10) within photobleached regions. This value is significantly positive (*p  0.00021) compared with E measured without
photobleaching (E  0.9%, n  10, white bar) or to energy transfer (E  6.6%, n  3, gray bar, right) between photobleached GFP (**p 
0.0000000056), which is abundantly expressed in the nucleus and immunolabeled Alexa 488-APC.
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Figure 2. The 15-amino acid and 20-amino acid repeat regions of APC each colocalize with topo II and localize to the nucleus. (A)
Schematic diagram of APC with domains implicated in nuclear function marked. Two NLSs are designated by thin pink lines in both
full-length APC and M3-APC. Five APC fragments expressed as GFP fusions are shown. (B) Colocalization of the GFP-fused APC fragments
with endogenous topo II in HCT116w cells. Of the five APC fragments, both M2 and M3 displayed significant nuclear localization and
partial colocalization with topo II. Bar, 5 m.
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binding domains in APC, we expressed five GFP-fused APC
fragments (Figure 2A) in HCT116w cells and compared
their localization with that of endogenous topo II (Figure
2B). As expected, GFP fused with either NT-APC, M1-APC,
or CT-APC predominantly localized to the cytoplasm (Fig-
ure 2B). M3-APC (amino acids 1211–2075) contains all 20-
amino acid repeats and two nuclear localization signals
(NLSs) (Zhang et al., 2000) and appeared to be located in the
nucleus when fused to GFP. GFP fused with M2-APC
(amino acids 959-1338) showed the most prominent overlap
with topo II in the nucleus. This region of APC contains all
four 15-amino acid -catenin binding repeats and one 20
amino acid repeat but no defined NLS.
Not only was GFP-M2-APC predominantly localized to
the nucleus but also HCT116w cells expressing this APC
fragment displayed abnormal DNA morphology, with nu-
clei looking condensed or fragmented (Figure 3A). To quan-
tify this phenotype, GFP-positive cells were scored at 24, 48,
and 72 h after transfection (Figure 3B and Supplemental
Table 1). GFP-M2-APC expression resulted in a dramatic
alteration in the DNA morphology, with 82% of the cells
displaying abnormal nuclei by 48 h after transfection. In
Figure 3. The 15-amino acid repeat region of
APC protein alters nuclear morphology. (A) Con-
focal immunofluorescence microscopy revealed
abnormal nuclei (condensed or fragmented) in
M2-APC–expressing HCT116w cells. Bar, 5 m.
(B) Nuclear phenotype of HCT116w cells ex-
pressing GFP-M2-APC (light bar), GFP-M3-APC
(dark bar), or GFP (white bar) at 24 and 48 h after
transfection. More than 80% of the M2-APC–ex-
pressing cells displayed abnormal nuclear mor-
phology by 48 h. (C) Nuclear phenotype of SW480
cells and HCA7 cells expressing GFP-M2-APC
(light bar) or GFP (white bar) at 48 h after trans-
fection. (B and C) Graphs represent analysis of
100 cells for each transfection in three indepen-
dent experiments, with error bars indicating SD.
Y. Wang et al.
Molecular Biology of the Cell4080
contrast, expression of GFP-M3-APC or GFP alone had little
effect on DNA morphology. Because the abnormal nuclear
morphology was not prevalent in M3-APC– or GFP-express-
ing cells, but rather was limited to cells expressing M2-APC,
this phenotype is not merely the cellular response to over-
expression of a nuclear protein. Moreover, abnormal nuclei
were also observed in SW480, HCA7 (Figure 3C and Sup-
plemental Table 1) and parental HCT116 cells (data not
shown) expressing GFP-M2-APC. Therefore, the abnormal
nuclear morphology is not restricted to the HCT116w cell
line and is not dependent on full-length endogenous APC.
The abnormal nuclear morphology resulting from M2-
APC expression resembled that seen in apoptotic cells. To
determine whether overexpression of M2-APC triggered ap-
optosis, we examined cells for various apoptotic markers
such as activated caspase-3 and annexin V, but we found no
evidence of apoptosis (data not shown). Furthermore, when
the cell cycle distribution of propidium iodide-stained cells
was analyzed using FACS analysis, the GFP-M2-APC–ex-
pressing cells had no detectable sub-G0 cell population in-
dicative of apoptotic cells (Figure 4A). Overall, the cell cycle
distribution of nontransfected cells was only slightly differ-
ent from that of GFP-expressing cells. In contrast, the GFP-
M2-APC–expressing cells showed a reproducible 2.5-fold
increase in the G2/M phase and an accompanying reduction
in the S phase compared with control cells (Figure 4B).
To determine whether this expanded G2/M population
reflected an arrest in the G2 or M phase of the cell cycle,
mitotic indices and phospho-histone H3 expression were
both evaluated at 24, 48, and 72 h after transfection (Figure
4, C and D). None of the M2-APC–expressing cells were
mitotic at any time, whereas control cells that were not
transfected or expressed GFP alone showed typical mitotic
indices at all times examined. These data suggest that the
expression of M2-APC results in G2 cell cycle arrest.
The Abnormal Nuclear Morphology after Expression of the
15-Amino Acid Repeat of APC Is Not Due to Altered
-Catenin
M2-APC comprises all four of the 15-amino acid -catenin
binding repeats and one of the 20-amino acid repeats in-
volved in -catenin down-regulation (Figure 2A). Activated
Wnt signaling resulting from stabilized -catenin was re-
cently reported to contribute to chromosome instability
(Aoki et al., 2007) and lead to G2 arrest (Olmeda et al., 2003).
Thus, we predicted that the abnormal nuclear morphology
seen in cells expressing M2-APC was dependent on M2-APC
association with and stabilization of nuclear -catenin. We
found -catenin expression and localization identical in
HCT116w cells expressing M2-APC, GFP, or nontrans-
fected (Figure 5A). Furthermore, immunoblots from total
lysates demonstrated comparable levels of -catenin in M2-
APC– and GFP-expressing cells (Figure 5D). Moreover, 1%
of the total -catenin coprecipitated with GFP-M2-APC (Fig-
ure 5B). In contrast, 10% of the total -catenin was precip-
itated along with endogenous full-length APC in parallel
experiments under the same experimental conditions (Fig-
ure 5C). Finally, -catenin activity measured in M2-APC–
expressing cells was comparable with that in GFP-express-
ing cells (Figure 5E). Thus, it seems unlikely that the
abnormal nuclear morphology and the G2 cell cycle arrest
observed in M2-APC–expressing cells result from -catenin
sequestration by M2-APC.
The 15-Amino Acid Repeat Region of APC Interacts with
Topo II
Our original identification of APC in complex with topo II,
an essential regulator of the G2/M transition prompted us to
examine whether M2-APC could interact with topo II and
possibly mediate the G2 arrest through this interaction.
HCT116w cells transiently expressing M2-APC had in-
creased levels of total topo II (Figure 6A) and the topo II
coprecipitated with GFP-M2-APC (Figure 6B). In contrast,
Figure 4. Expression of the 15-amino acid repeat region of APC
results in G2 accumulation. (A) Histograms showing representative
FACS displays of cell cycle distribution assessed by propidium
iodide staining. UN, untransfected cells. For both GFP- and GFP-
M2-APC–expressing cells, only GFP-positive cells are displayed. (B)
FACS data from three independent experiments. The fraction of
cells in G2/M doubled, and the S phase decreased by half for cells
expressing GFP-M2-APC compared with the untransfected control
cells or cells expressing only GFP. Values for G0/G1, S, and G2/M,
respectively, are 35.6  2.1, 40.9  2.4, and 23.5  3.3% (for un-
transfected); 37.7  1.3, 41.0  9.6, and 21.3  8.5% (for GFP); and
28.0  5.6, 18.1  5.6, and 53.9  8.9% (for M2-APC). For each
transfection, 15,000 GFP-positive cells were analyzed. (C) Mitotic
events assessed after DAPI staining. One hundred randomly chosen
M2-APC– or GFP-expressing cells were analyzed from three inde-
pendent experiments at 24, 48, and 72 h after transfection. None of
the M2-APC–expressing cells appeared to be mitotic. A small num-
ber of the GFP-expressing cells were mitotic. (D) Representative
immunofluorescence confocal microscopy of mitotic marker phos-
pho-histone H3 from three independent experiments. No M2-APC–
expressing cells were positive for phospho-histone H3, whereas a
few GFP-expressing cells were positive. Arrowhead indicates a cell
that is positive for both GFP and phospho-histone H3. Bar, 10 m.
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no topo II precipitated with the GFP in cells expressing
GFP alone. Because M2-APC and topo II interact, it is
possible that M2-APC can influence the activity of topo II.
To test this directly, in vitro DNA relaxation and decatena-
tion assays were performed using purified recombinant pro-
teins topo II and M2-APC. Purified M2-APC stimulated
topo II activity in both DNA relaxation (Figure 6C) and
decatenation assays (data not shown). This enhancement
was apparent when purified M2-APC was provided at equal
molar concentration to the topo II and was further pro-
nounced with 4 times more M2-APC in the reaction (Figure
6C). In the absence of topo II, purified M2-APC did not
relax the DNA (Figure 6C) or bind to the DNA slowing its
migration (data not shown). Using a higher concentration of
recombinant topo II, M2-APC still enhanced topo II ac-
tivity (Figure 6D). In contrast, bovine serum albumin (BSA)
Figure 5. Expression of the 15-amino acid repeat re-
gion of APC does not alter -catenin expression or
localization. (A) Confocal immunofluorescence micros-
copy reveals similar -catenin localization in M2-APC–
and GFP-expressing HCT116w cells. Note that the nu-
cleus (right) is abnormal in the M2-APC–expressing
cell. Bar, 5 m. (B) Less than 1% of the total -catenin
coimmunoprecipitated with GFP-M2-APC by using a
GFP antibody (M2), and none coimmunoprecipitated
with GFP alone (GFP). Ten percent input is 25 g of
total protein. Transfection efficiency was 50%. (C)
Nearly 10% of the total -catenin coimmunoprecipitated
with endogenous APC. Ten percent input is 30 g of
total protein. Representative blots from five indepen-
dent experiments. (D) Western blot reveals comparable
levels of total -catenin in M2-APC- (M2) and GFP-
expressing (GFP) cells. Equivalent amounts of total pro-
tein from whole cell lysates were loaded. (B and D)
Representative blots from three independent experi-
ments. (E) Cells were cotransfected with GFP-M2-APC
or GFP, SuperTOP-flash or FOP-flash reporters, and
pRL-TK Renilla luciferase plasmid. Luciferase activities
were determined 24 h after transfection and normalized
against both pRL-TK Renilla activity and FOP-flash re-
porter activity. Values are mean  SD for triplicate
samples from a representative experiment.
Figure 6. The 15-amino acid repeat region of APC
associates with topo II and enhances topo II activity.
(A) Increased expression of topo II in M2-APC–ex-
pressing cells compared with GFP-expressing cells.
Equivalent total protein loaded in each lane. (B) Topo
II coimmunoprecipitates with M2-APC, but not with
GFP. Ten percent input is 25 g of total protein. The star
marks migration of antibody heavy chain. (A and B)
Representative blots from five independent experi-
ments. (C and D) Representative topo II DNA relax-
ation assays from five independent experiments. R, re-
laxed plasmid DNA; S, supercoiled plasmid. (C)
Purified recombinant human topo II (0.35 M) slightly
relaxed supercoiled plasmid DNA (lane 2). Addition of
purified recombinant M2-APC (0.35 or 1.75 M) to the
reaction resulted in progressively enhanced topo II
plasmid relaxation activity (lanes 3 and 4). M2-APC
did not have plasmid relaxation activity in the ab-
sence of topo II (lane 5). (D) Using a higher concen-
tration of topo II (0.7 M), the addition of BSA (0.7
M) did not enhance the plasmid relaxation activity,
but rather slightly inhibited it (compare lanes 2 and
3). M2-APC (0.7 M) enhanced the plasmid relaxation
activity (lane 5).
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protein at an equal molar ratio slightly inhibited topo II
activity (Figure 6D). These in vitro assays provide additional
support for a functional interaction between APC and topo
II. Together, our data implicate topo II as a mediator of
abnormal DNA morphology and G2 arrest associated with
exogenous M2-APC expression.
DISCUSSION
In this study, we identify a novel interaction between the
tumor suppressor protein APC and topo II. This interaction
was demonstrated by colocalization, reciprocal coimmuno-
precipitation, FRET, and functional assays. Topo II inter-
acts with the 15-amino acid repeat region of APC (M2-APC,
amino acids 959-1338). When overexpressed in colon cancer
cell lines, M2-APC located predominantly to the nucleus.
Cells expressing M2-APC displayed abnormal nuclear mor-
phology and were inhibited in the G2 phase of the cell cycle.
Although M2-APC could bind -catenin, we found no evi-
dence supporting a role for -catenin in the observed phe-
notypes. Our data suggest a novel role for nuclear APC in
the regulation of cell cycle progression, potentially through
an interaction between topo II and the 15-amino acid re-
peat region of APC.
The GFP–M2-APC protein was not expected to locate
predominantly to the nucleus. Although endogenous full-
length APC exists in both cytoplasm and nucleus (Neufeld
and White, 1997; Anderson et al., 2002), the classic NLSs that
are thought to facilitate nuclear localization of APC (Zhang
et al., 2000) are not present in the M2-APC fragment. The
M2-APC region is retained in most truncated forms of APC
associated with colorectal cancer and these truncated APC
proteins are capable of nucleocytoplasmic shuttling (Fag-
man et al., 2003). However, the nuclear import ability of
these truncated APC proteins has been attributed to the
armadillo repeat region (amino acids 334–625), not the 15-
amino acid repeat region (Galea et al., 2001). With an esti-
mated molecular weight of 70 kDa, GFP-M2-APC is too
large to enter the nucleus by diffusion, which has a size
limitation of 30–50 kDa (Schulz and Peters, 1987; Mattaj and
Englmeier, 1998; Moroianu, 1999). Therefore, M2-APC likely
contains a nonstandard NLS or is carried into the nucleus by
a nuclear binding partner. Because here we show that M2-
APC binds to the abundant nuclear protein topo II, it is
possible that nuclear entry of M2-APC is facilitated in part
by topo II. APC has also been reported to bind PCNA
through the M2 region (Narayan et al., 2005), and we have
confirmed that PCNA coimmunoprecipitates with M2-APC
(data not shown). We reason that other nuclear proteins,
such as PCNA, might contribute to the nuclear entry of
M2-APC as well.
As an abundant nuclear protein, topo II is involved in
several processes throughout the cell cycle, including tran-
scription, DNA replication, chromatin recombination and
organization, and regulation of the G2 decatenation check-
point (Wang, 1996; Nitiss, 1998; Fortune and Osheroff, 2000;
Champoux, 2001; Wang, 2002; McClendon and Osheroff,
2007). It is possible that the topo II we consistently found
associated with endogenous APC and with the M2-APC
fragment (Figures 1B and 6B) corresponds to a specific pool
of topo II involved in regulation of the G2/M transition.
Other pools of topo II might be positioned near replicating
heterochromatin during S phase (Agostinho et al., 2004),
tightly associated with DNA to aid chromosome assembly at
the G2/M transition (Earnshaw and Heck, 1985; Gasser et al.,
1986; Swedlow and Hirano, 2003), responsible for transcrip-
tion regulation at G1/S (Huang et al., 2007), or involved in
chromosome segregation at the exit of mitosis (Hirano and
Mitchison, 1993; Downes et al., 1994; Grue et al., 1998). One
explanation for the rather modest amount of topo II that
coprecipitated with endogenous APC is that the interaction
between APC and topo II is transient, only occurring at a
specific point of the cell cycle.
APC is not the first tumor suppressor protein to interact
with topo II. BRCA1 (Yamane et al., 2003; Lou et al., 2005),
RB (Bhat et al., 1999), and p53 (Cowell et al., 2000) each bind
to topo II and thereby effect topo II functions. A recent
report also links topo II to the oncoprotein -catenin and its
transcription cofactor TCF (Huang et al., 2007). Overexpres-
sion of topo II led to enhanced -catenin/TCF transcription
activity, whereas expression of a constitutively active -cate-
nin led to increased topo II activity measured in a whole
cell lysate. We predict that -catenin/TCF associates with a
topo II pool that is involved in transcription regulation at
G1/S. It is possible that this interaction is indirect and me-
diated by APC. APC has been found in association with the
enhancer region of genes regulated by -catenin/TCF (Si-
erra et al., 2006). In contrast, we suspect that the APC/topo
II interaction we described here is direct. Purified recom-
binant human M2-APC enhanced the plasmid relaxation
activity of purified topo II in our in vitro assays which
lacked other potential linker proteins (Figure 6, C and D).
Moreover, M2-APC does not seem to bind directly to DNA
as determined by gel shift assays (data not shown). We
propose that the pool of topo II that interacts with APC to
impact G2 cell cycle transition is separate from the pool
involved in -catenin mediated transcription.
We report that the topo II protein level was higher in
cells expressing GFP-M2-APC than in GFP-expressing cells
(Figure 6A). This observation is consistent with previous
reports that topo II levels peak in G2 (Heck et al., 1988). We
also report that purified M2-APC enhances topo II activity
in an in vitro relaxation assay (Figure 6, C and D). Cell cycle
progression from G2 to M is likely dependent on the main-
tenance of topo II activity at a precise level. Indeed, Ep-
stein-Barr virus kinase BGLF4 both stimulates topo II ac-
tivity and induces premature chromosome condensation
similar to the abnormal DNA morphology we report with
M2-APC expression (Lee et al., 2007). Furthermore, protein
kinase C regulates topo II activity specifically during S
phase with aberrant activation of topo II by protein kinase
C leading to apoptosis (Yoshida et al., 2006). At the simplest
level, we propose that endogenous APC regulates topo II
activity and thereby facilitates G2-M cell cycle progression.
Topo II activity is essential for the chromatin decatena-
tion required before mitosis (Downes et al., 1994). APC lo-
cates near centrosomes during early and late stages of mi-
tosis and has also been implicated in maintenance of
chromatin structure (Olmeda et al., 2003; Huang et al., 2007).
Therefore, we cannot exclude the possibility that both APC
and topo II provide multiple functions throughout the
G2/M transition. We propose that a functional interaction
between APC and topo II results in regulation of topo II
activity. Without this regulation, cell cycle progression
would be affected. Given that truncated APC found in most
colorectal cancers includes the M2-APC region, it is possible
that topo II regulation is maintained in these cancers. In
this scenario, retention of the topo II regulatory domain in
truncated APC might be essential for cell viability. Alterna-
tively, truncated APC proteins associated with cancer might
behave more like the M2-APC fragment and be unable to
effectively regulate topo II activity. The resulting stimula-
tion of DNA cleavage by topo II would be predicted to
induce chromosome instability, a hallmark of cancer.
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Together, we propose a novel function for the tumor
suppressor APC in regulation of the G2-M cell cycle transi-
tion, potentially through interaction with topo II. Future
investigation will be needed to determine the precise under-
lying mechanism by which M2-APC promotes G2 cell cycle
arrest. Such studies will potentially reveal a novel activity of
APC in tumor suppression. This expanded role of the tumor
suppressor APC has obvious implications in explaining the
deregulation of topo II in colon cancer tissue (Murphy et al.,
2001) and for the use of topo II inhibitors as chemothera-
peutic agents to treat colorectal cancer.
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